Skip to main content
SLAS Europe 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Short Course
Short Course
On Demand
On Demand

  1. Home

  • Wednesday, May 24th
    11:30 – 13:00 CET
    Tagreted Protein Degradation
    Room/Location: 324 (Level +2)
    David McClymont, PhD – Horizon Discovery Ltd
    Shaping the Future of Therapeutics
  • Wednesday, May 24th
    11:30 – 12:00 CET
    Mining the functional degradome with unbiased PROTEINi screening
    Room/Location: 324 (Level +2)
    Benedict CS Cross, n/a – PhoreMost Ltd
    Shaping the Future of Therapeutics
  • Wednesday, May 24th
    12:00 – 12:30 CET
    Development of Direct to Biology platform for rapidly evaluating PROTACs for Targeted Protein Degradation
    Room/Location: 324 (Level +2)
    Shaping the Future of Therapeutics
  • Wednesday, May 24th
    12:30 – 13:00 CET
    High Throughout Mass Spectrometry (HTMS), combining Acoustic Ejection MS Innovation and Efficient Assay Development & Screening Capabilities to Accelerate Drug Discovery
    Room/Location: 324 (Level +2)
    Celine Legros, PhD (she/her/hers) – Eurofins Discovery
    Shaping the Future of Therapeutics
  • Wednesday, May 24th
    14:30 – 16:00 CET
    RNA-based Therapeutics
    Room/Location: 324 (Level +2)
    Gianluigi Lichinchi, PhD (he/him/his) – Roche Pharma Research and Early Development
    Shaping the Future of Therapeutics
  • Wednesday, May 24th
    14:30 – 15:00 CET
    Design and screening of therapeutic antisense oligonucleotides
    Room/Location: 324 (Level +2)
    Gianluigi Lichinchi, PhD (he/him/his) – Roche Pharma Research and Early Development
    Shaping the Future of Therapeutics
  • Wednesday, May 24th
    15:00 – 15:30 CET
    Personalized Medicine – a technical challenge for GMP Manufacturing of mRNA
    Room/Location: 324 (Level +2)
    Shaping the Future of Therapeutics
  • Wednesday, May 24th
    15:30 – 16:00 CET
    A Molecular and Computational Toolbox to Enable Therapeutic A-to-I RNA Editing
    Room/Location: 324 (Level +2)
    Adrian Wrangham Briggs, PhD – Shape Therapeutics
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    10:30 – 12:30 CET
    Cell Therapies
    Room/Location: 324 (Level +2)
    David T. Rodgers, PhD (he/him/his) – Shoreline Biosciences
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    10:30 – 11:00 CET
    Changing Lanes For Cell Therapy
    Room/Location: 324 (Level +2)
    David T. Rodgers, PhD (he/him/his) – Shoreline Biosciences
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    11:00 – 11:30 CET
    Artificial Intelligence and Automation enabling rapid, widely available autologous CAR-T cell therapy
    Room/Location: 324 (Level +2)
    Laura Herbst – Fraunhofer-Institute for Production Technology
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    11:30 – 12:00 CET
    Best practices of 2D and 3D CAR T cytotoxicity assay using high throughput plate based image cytometry
    Room/Location: 324 (Level +2)
    Scott Cribbes, PhD – Nexcelom from PerkinElmer
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    12:00 – 12:30 CET
    Accelerating Precision Medicine - Turning data into insights using AI and automation
    Room/Location: 324 (Level +2)
    Matt Gafencu, BS EE (he/him/his) – Amazon Web Services (AWS)
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    14:30 – 16:00 CET
    Gene Therapies (ELRIG)
    Room/Location: 324 (Level +2)
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    14:30 – 15:00 CET
    Development of Innovative Regenerative Therapeutic Strategies by Translating Bacterial Ingenuity of Reprogramming and Organ Growth
    Room/Location: 324 (Level +2)
    Anura Rambukkana, PhD (he/him/his) – University of Edinburgh
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    15:00 – 15:30 CET
    Novel technologies for development of safer therapeutic genome editing medicines
    Room/Location: 324 (Level +2)
    Shaping the Future of Therapeutics
  • Thursday, May 25th
    15:30 – 16:00 CET
    Meeting the gene editing potential of cell line engineering with image analysis, abstraction and automation
    Room/Location: 324 (Level +2)
    David McClymont, PhD – Horizon Discovery Ltd
    Shaping the Future of Therapeutics